| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Epithelial ovarian cancer is a highly lethal malignancy and overcoming chemoresistance is the major challenging in treating ovarian cancer patients. Even though ovarian cancer stem cells have not been completely elucidated, these cells are believed to play crucial roles in chemoresistance and relapse of ovarian cancer. Previous studies have supported the premise that EpCAM is one of the cell surface markers associated with cancer stem cells in many solid cancers, including ovarian cancer.
In this study, we demonstrated the functional role of EpCAM in the resistance to platinum-based chemotherapy. We also found that EpCAM-targeted therapies using adecatumumab showed a significant inhibition of ovarian cancer cell proliferation and tumor growth in in vitro assays and in vivo mouse models.
EpCAM expression may represent a promising therapeutic target to effectively extirpate the cancer stem cells as the root of ovarian cancer.
|
